DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

Published:2017-10 Issue:10 Volume:28 Page:2451-2457
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Martinez-Marti A.,Felip E.,Matito J.,Mereu E.,Navarro A.,Cedrés S.,Pardo N.,Martinez de Castro A.,Remon J.,Miquel J.M.,Guillaumet-Adkins A.,Nadal E.,Rodriguez-Esteban G.,Arqués O.,Fasani R.,Nuciforo P.,Heyn H.,Villanueva A.,Palmer H.G.,Vivancos A.

Funder

Banco Bilbao Vizcaya Argentaria

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/10/2451/24168912/mdx396.pdf

Reference32 articles.

1. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

3. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J Clin Oncol,2013

4. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

5. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04

2. Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy;Frontiers in Immunology;2024-01-12

3. The clinical implication and translational research of OSCC differentiation;British Journal of Cancer;2024-01-05

4. Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer;Cell Communication and Signaling;2023-04-11

5. Non-Small Cell Lung Cancer Brain Metastasis: The Link between Molecular Mechanisms and Novel Therapeutic Approaches;Cancer Metastasis - Molecular Mechanism and Clinical Therapy;2023-03-08